---
schema_version: '1.0'
id: government-20261112-f33715
title: 'Schedules of Controlled Substances: Placement of Oveporexton in Schedule IV'
content_kind: government-document
url: https://www.federalregister.gov/documents/2026/11/12/2026-23075/schedules-of-controlled-substances-placement-of-oveporexton-in-schedule-iv
url_hash: f33715ac908f1a97d698c0e09a8c8445b3efb464789be4d3421d9edc6efba58a
canonical_url: https://www.federalregister.gov/documents/2026/11/12/2026-23075/schedules-of-controlled-substances-placement-of-oveporexton-in-schedule-iv
source: us-federal-register
category: government/us
category_raw: Rule
country: us
region: us
tags:
- Administrative practice and procedure
- Drug traffic control
- Reporting and recordkeeping requirements
lang: en
published_at: '2026-11-12T00:00:00Z'
fetched_at: '2026-11-11T15:00:53.949614Z'
updated_at: '2026-11-12T04:55:03Z'
status: published
content_hash: 59cc5565a505d63c0a0eeb9efe576ff9bbb93d3b2a8868089b4d66fbc5fd45bb
content_changed_at: null
license_note: full
license_basis: public-domain-17usc105
body_available: false
attribution: 'Source: Office of the Federal Register, National Archives and Records
  Administration'
license_rule: source:us-federal-register
summary: On August 5, 2026, the United States Food and Drug Administration (FDA) approved
  a new drug application for Orzeyful (oveporexton) for the treatment of narcolepsy
  type 1 in adults. The Department of Health and Human Services (HHS) provided the
  Drug Enforcement Administration (DEA) with a scheduling recommendation to place
  oveporexton, chemically known as N-[(2S,3R)-2-[[3-(3,5- difluorophenyl)-2-fluorophenyl]methyl]-4,4-difluoro-1-(2-hydroxy-2-
  methylpropanoyl)pyrrolidin-3-yl]ethanesulfonamide, in schedule IV of the Controlled
  Substances Act (CSA). In accordance with the CSA, as amended by the Improving Regulatory
  Transparency for New Medical Therapies Act, DEA is hereby issuing an interim final
  rule placing oveporexton, including its salts, isomers and salts of isomers whenever
  the existence of such salts, isomers, and salts of isomers is possible, in schedule
  IV of the CSA.
summary_source: official
summary_en: On August 5, 2026, the United States Food and Drug Administration (FDA)
  approved a new drug application for Orzeyful (oveporexton) for the treatment of
  narcolepsy type 1 in adults. The Department of Health and Human Services (HHS) provided
  the Drug Enforcement Administration (DEA) with a scheduling recommendation to place
  oveporexton, chemically known as N-[(2S,3R)-2-[[3-(3,5- difluorophenyl)-2-fluorophenyl]methyl]-4,4-difluoro-1-(2-hydroxy-2-
  methylpropanoyl)pyrrolidin-3-yl]ethanesulfonamide, in schedule IV of the Controlled
  Substances Act (CSA). In accordance with the CSA, as amended by the Improving Regulatory
  Transparency for New Medical Therapies Act, DEA is hereby issuing an interim final
  rule placing oveporexton, including its salts, isomers and salts of isomers whenever
  the existence of such salts, isomers, and salts of isomers is possible, in schedule
  IV of the CSA.
summary_omitted_reason: null
redistribution: true
keywords_en:
- '2027: Again, Tinubu rules out fuel subsidy return, tackles opponents'
- Administrative practice and procedure
- Controlled
- Drug traffic control
- Justice Department
- Oveporexton
- Placement
- public policy
- Reporting and recordkeeping requirements
- Schedule
- Schedules
- Substances
- United States government
entities_en:
- name: '2027: Again, Tinubu rules out fuel subsidy return, tackles opponents'
  type: event
- name: Justice Department
  type: organization
topics_en:
- public policy
- United States government
numeric_facts: []
provenance:
  doc_id: 2026-23075
  doc_id_scheme: fr_docnum
  issuer:
  - Justice Department
  - Drug Enforcement Administration
  doc_type: Rule
  subtype: null
  action: Interim final rule; request for comments.
  significant: null
entities:
- name: Justice Department
  type: organization
- name: '2027: Again, Tinubu rules out fuel subsidy return, tackles opponents'
  type: event
key_facts: []
related: []
related_auto:
- name: House Oversight Committee
  type: organization
  weight: 1.0
- name: Epstein associates
  type: UNKNOWN
  weight: 1.0
computed_at: '2026-11-12T04:54:41Z'
---

# Schedules of Controlled Substances: Placement of Oveporexton in Schedule IV

## TL;DR
On August 5, 2026, the United States Food and Drug Administration (FDA) approved a new drug application for Orzeyful (oveporexton) for the treatment of narcolepsy type 1 in adults. The Department of Health and Human Services (HHS) provided the Drug Enforcement Administration (DEA) with a scheduling recommendation to place oveporexton, chemically known as N-[(2S,3R)-2-[[3-(3,5- difluorophenyl)-2-fluorophenyl]methyl]-4,4-difluoro-1-(2-hydroxy-2- methylpropanoyl)pyrrolidin-3-yl]ethanesulfonamide, in schedule IV of the Controlled Substances Act (CSA). In accordance with the CSA, as amended by the Improving Regulatory Transparency for New Medical Therapies Act, DEA is hereby issuing an interim final rule placing oveporexton, including its salts, isomers and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule IV of the CSA.

## Key Points
- Administrative practice and procedure / Drug traffic control / Reporting and recordkeeping requirements

## Details
(本文なし。リンク先参照)

## Source
元記事: [Schedules of Controlled Substances: Placement of Oveporexton in Schedule IV](https://www.federalregister.gov/documents/2026/11/12/2026-23075/schedules-of-controlled-substances-placement-of-oveporexton-in-schedule-iv) — published 2026-11-12T00:00:00Z